401 related articles for article (PubMed ID: 23873327)
1. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
Ling H; Packard KA; Burns TL; Hilleman DE
Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327
[TBL] [Abstract][Full Text] [Related]
2. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
Thadani U
Expert Opin Pharmacother; 2012 Dec; 13(17):2555-63. PubMed ID: 23121448
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with ranolazine in a veteran population with chronic stable angina.
Reeder DN; Gillette MA; Franck AJ; Frohnapple DJ
Ann Pharmacother; 2012 Jan; 46(1):42-50. PubMed ID: 22215689
[TBL] [Abstract][Full Text] [Related]
4. Costs and clinical outcomes associated with use of ranolazine for treatment of angina.
Phelps CE; Buysman EK; Gomez Rey G
Clin Ther; 2012 Jun; 34(6):1395-1407.e4. PubMed ID: 22608105
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
Page RL; Ghushchyan V; Read RA; Hartsfield CL; Koch BR; Nair KV
Am J Cardiol; 2015 Nov; 116(9):1321-8. PubMed ID: 26358510
[TBL] [Abstract][Full Text] [Related]
6. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Stone PH; Gratsiansky NA; Blokhin A; Huang IZ; Meng L;
J Am Coll Cardiol; 2006 Aug; 48(3):566-75. PubMed ID: 16875985
[TBL] [Abstract][Full Text] [Related]
7. Ranolazine refractory angina registry: 1-year results.
Bennett NM; Iyer V; Arndt TL; Garberich RF; Traverse JH; Johnson RK; Poulose AK; Lips A; Morgan JM; Henry TD
Crit Pathw Cardiol; 2014 Sep; 13(3):96-8. PubMed ID: 25062392
[TBL] [Abstract][Full Text] [Related]
8. Ranolazine for the treatment of refractory angina in a veterans population.
Greene RS; Rangel RM; Edwards KL; Chastain LM; Brouse SD; Alvarez CA; Collins LJ; Brilakis ES; Banerjee S
Cardiovasc Revasc Med; 2012; 13(2):141.e1-5. PubMed ID: 21856249
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
[TBL] [Abstract][Full Text] [Related]
10. Ranolazine (Ranexa) for chronic stable angina.
Ndegwa S
Issues Emerg Health Technol; 2007 Jun; (99):1-6. PubMed ID: 17595750
[TBL] [Abstract][Full Text] [Related]
11. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials.
Wenger NK; Chaitman B; Vetrovec GW
Am J Cardiol; 2007 Jan; 99(1):11-8. PubMed ID: 17196454
[TBL] [Abstract][Full Text] [Related]
12. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.
Cocco G; Rousseau MF; Bouvy T; Cheron P; Williams G; Detry JM; Pouleur H
J Cardiovasc Pharmacol; 1992 Jul; 20(1):131-8. PubMed ID: 1383622
[TBL] [Abstract][Full Text] [Related]
13. Ranolazine: clinical applications and therapeutic basis.
Hawwa N; Menon V
Am J Cardiovasc Drugs; 2013 Feb; 13(1):5-16. PubMed ID: 23335347
[TBL] [Abstract][Full Text] [Related]
14. [Symptomatic coronary heart disease therapy: ranolazine reduces frequency of angina in diabetic patients].
MMW Fortschr Med; 2013 Mar; 155 Spec No 1(1):20. PubMed ID: 24260912
[No Abstract] [Full Text] [Related]
15. Ranolazine for the management of coronary artery disease.
Cheng JW
Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris.
Kohn CG; Parker MW; Limone BL; Coleman CI
Am J Cardiol; 2014 Apr; 113(8):1306-11. PubMed ID: 24560062
[TBL] [Abstract][Full Text] [Related]
17. Ranolazine: an antianginal drug with antiarrhythmic properties.
Tamargo J; Caballero R; Delpón E
Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
Koren MJ; Crager MR; Sweeney M
J Am Coll Cardiol; 2007 Mar; 49(10):1027-34. PubMed ID: 17349881
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
Rousseau MF; Pouleur H; Cocco G; Wolff AA
Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536
[TBL] [Abstract][Full Text] [Related]
20. Use of ranolazine in patients with stable angina pectoris.
Khera S; Kolte D; Aronow WS
Cardiology; 2014; 128(3):251-8. PubMed ID: 24852049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
